microRNAs linked to protection from autoimmune diseases, new research finds.

Melbourne's Antisense Therapeutics (ASX:ANP) is planning to restart the phase IIa trial of its lead drug candidate for multiple sclerosis ATL1102 before the end of the year, following recommendations from its advisory board.

A new environment for pharmaceutical companies is on the horizon and it will be the fittest who survive, predicts Ian Nisbet.

There is no reason why an Australian biotech company couldn't be the next Amgen, says Chris Henney, the US scientist turned serial entrepreneur who has a seat on Adelaide company Bionomics' board of directors. But he warns that will likely have to move to the US in order to pursue their goal, in part due to the lack of capital available for company growth in Australia.